"10.1371_journal.pone.0084225","plos one","2013-12-27T00:00:00Z","Dimo Dietrich; Maria Jung; Svenja Puetzer; Annette Leisse; Emily Eva Holmes; Sebastian Meller; Barbara Uhl; Philipp Schatz; Claudia Ivascu; Glen Kristiansen","University Hospital Bonn (UKB), Institute of Pathology, Bonn, Germany; Metanomics Health GmbH, Berlin, Germany; Roche Pharma AG, Hematology/Oncology, Grenzach-Wyhlen, Germany","Conceived and designed the experiments: DD MJ PS CI GK. Performed the experiments: MJ SP AL BU SM. Analyzed the data: DD MJ. Wrote the paper: DD MJ EEH GK.","Claudia Ivascu and Philipp Schatz are employed at Metanomics Health GmbH and Roche Pharma AG, respectively, whose companies funded time on this study. Dimo Dietrich, Claudia Ivascu and Philipp Schatz have been employees and are stockholders of Epigenomics AG, a company that aims to commercialize the DNA methylation markers SEPT9 and SHOX2. Dimo Dietrich and Philipp Schatz are coinventors and own patents on methylation biomarkers and related technologies. Patents: “A Method for Amplification of Nucleic Acids” (WO2006113770), “A Method for the Carry-over Protection in DNA Amplification Systems Targeting Methylation Analysis Achieved by a Modified Pre-treatment of nucleic Acids” (WO2006040187). These patents are commercially exploited by Epigenomics AG. Dimo Dietrich and Philipp Schatz receive inventors compensation from Epigenomics AG. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Dimo Dietrich","DD",10,TRUE,5,5,2,4,TRUE,TRUE,FALSE,0,NA,FALSE
